DE3789504D1 - Optisch aktive azetidinone und verfahren zu deren herstellung. - Google Patents

Optisch aktive azetidinone und verfahren zu deren herstellung.

Info

Publication number
DE3789504D1
DE3789504D1 DE88900113T DE3789504T DE3789504D1 DE 3789504 D1 DE3789504 D1 DE 3789504D1 DE 88900113 T DE88900113 T DE 88900113T DE 3789504 T DE3789504 T DE 3789504T DE 3789504 D1 DE3789504 D1 DE 3789504D1
Authority
DE
Germany
Prior art keywords
production
optically active
active azetidinone
azetidinone
optically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE88900113T
Other languages
English (en)
Other versions
DE3789504T2 (de
Inventor
Takeo Yoshioka
Machiko Watanabe
Yasuo Fukagawa
Tomoyuki Ishikura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanraku Inc
Original Assignee
Sanraku Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanraku Inc filed Critical Sanraku Inc
Application granted granted Critical
Publication of DE3789504D1 publication Critical patent/DE3789504D1/de
Publication of DE3789504T2 publication Critical patent/DE3789504T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE3789504T 1986-12-22 1987-12-18 Optisch aktive azetidinone und verfahren zu deren herstellung. Expired - Fee Related DE3789504T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP61303915A JPS63156788A (ja) 1986-12-22 1986-12-22 光学活性アゼチジノン類
PCT/JP1987/000991 WO1988004656A1 (en) 1986-12-22 1987-12-18 Optically active azetidinones and process for production thereof

Publications (2)

Publication Number Publication Date
DE3789504D1 true DE3789504D1 (de) 1994-05-05
DE3789504T2 DE3789504T2 (de) 1994-08-18

Family

ID=17926801

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3789504T Expired - Fee Related DE3789504T2 (de) 1986-12-22 1987-12-18 Optisch aktive azetidinone und verfahren zu deren herstellung.

Country Status (5)

Country Link
US (1) US4939248A (de)
EP (1) EP0295308B1 (de)
JP (1) JPS63156788A (de)
DE (1) DE3789504T2 (de)
WO (1) WO1988004656A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03123770A (ja) * 1989-10-06 1991-05-27 Mercian Corp アゼチジノン誘導体及びその製法
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
CA2434430A1 (en) * 2001-01-26 2002-08-01 Harry R. Davis The use of substituted azetidinone compounds for the treatment of sitosterolemia
MXPA03006727A (es) * 2001-01-26 2003-10-24 Schering Corp Combinaciones de acido nicotinico y derivados del mismo con inhibidor(es) de la absorcion de los esteroles, y tratamiento para indicaciones vasculares.
NZ542090A (en) * 2001-01-26 2006-09-29 Schering Corp Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
SK288217B6 (sk) * 2001-01-26 2014-08-05 Merck Sharp & Dohme Corp. Zmes, terapeutická kombinácia, farmaceutický prostriedok a ich použitie
EP1785144A3 (de) * 2001-01-26 2007-05-23 Shering Corporation Kombinationen von Gallensäurebinder(n) und Sterolabsorptionshemmer(n) und entsprechende Behandlung für vaskuläre Indikationen
CZ20032031A3 (cs) * 2001-01-26 2003-12-17 Schering Corporation Farmaceutický prostředek
AR038956A1 (es) * 2001-05-25 2005-02-02 Schering Corp Uso de un compuesto que regula la produccion o niveles de peptidos beta amiloides para la manufactura de un medicamento para tratar la enfermedad de alzheimer y/o para regular dichos niveles de peptidos amiloides beta en un sujeto
CA2460340C (en) * 2001-09-21 2011-02-15 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
PT1427409E (pt) * 2001-09-21 2008-11-27 Schering Corp Métodos para tratar ou para impedir a inflamação vascular utilizando inibidor(es) de absorção de esteróis
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
WO2004043457A1 (en) * 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
ATE406364T1 (de) 2003-03-07 2008-09-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
WO2004081004A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
MXPA05009501A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
US20050096307A1 (en) * 2003-11-05 2005-05-05 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0146735A1 (de) * 1983-11-23 1985-07-03 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Optisch einheitliche beta-Lactame

Also Published As

Publication number Publication date
EP0295308B1 (de) 1994-03-30
JPS63156788A (ja) 1988-06-29
US4939248A (en) 1990-07-03
DE3789504T2 (de) 1994-08-18
WO1988004656A1 (en) 1988-06-30
EP0295308A1 (de) 1988-12-21

Similar Documents

Publication Publication Date Title
DE3769400D1 (de) Verkapselte halbleiteranordnung und verfahren zu deren herstellung.
DE3786097D1 (de) Polysiloxazane, silikonoxynitrid-fasern und verfahren zu deren herstellung.
DE3672271D1 (de) Reinigungsmittel, deren bestandteile und verfahren zu deren herstellung.
DE3766878D1 (de) Prothesenteil sowie verfahren zu seiner herstellung.
DE3763993D1 (de) Leichtisolierplatten und verfahren zu deren herstellung.
DE68907057D1 (de) Naehrstoffzusammensetzung und verfahren zu deren herstellung.
DE3789504D1 (de) Optisch aktive azetidinone und verfahren zu deren herstellung.
DE3586822D1 (de) Halbleiteranordnung und verfahren zu deren herstellung.
DE3688604D1 (de) Optisches geraet und verfahren zu dessen herstellung.
DE3751243D1 (de) Opto-elektronisches Bauelement und Verfahren zu seiner Herstellung.
DE3582576D1 (de) Dithioketo-pyrrolo-pyrrole, verfahren zu deren herstellung und verwendung.
DE3675741D1 (de) Vernetzte copolyamidimide und verfahren zu deren herstellung.
DE3780532D1 (de) Amphoterische staerke und verfahren zu deren herstellung.
DE68917798D1 (de) Anschlussstruktur und Verfahren zu deren Herstellung.
DE3782201D1 (de) Halbleiterphotosensor und verfahren zu dessen herstellung.
DE3762846D1 (de) Optisch aktive tolanderivate und verfahren zu deren herstellung.
DE3874372D1 (de) Polysiloxan-polyimide und verfahren zu deren herstellung.
DE3782952D1 (de) Supraleitende dipolmagnete und verfahren zu deren herstellung.
DE3686597D1 (de) Uricase und verfahren zu deren herstellung.
DE68902670D1 (de) Ks-506 verbindungen und verfahren zu deren herstellung.
DE3677740D1 (de) 2-iod-perfluor-2-methylalkane, verfahren zu deren herstellung und deren verwendung.
DE3686561D1 (de) Klebstrukturen und verfahren zu deren herstellung.
DE3865927D1 (de) Tetrahydroindazolyl-benzoxazine, verfahren zu deren herstellung und deren anwendung.
DE3886445D1 (de) Optisch-aktive Verbindungen und Verfahren zu deren Herstellung.
DE3576342D1 (de) Penam-derivate und verfahren zu deren herstellung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee